



Annual General Meeting elects new Supervisory Board members

- Draft resolutions approved with large majorities
- Management confirms CytoTools AG strategy

Darmstadt, July 23, 2014 – Shareholders at yesterday’s Annual General Meeting of CytoTools AG approved all draft resolutions proposed by the management with large majorities. Overall, 33.21% of the share capital and voting stock in CytoTools AG were represented at the shareholders’ meeting. Following Dr. Weissbach’s move from the Supervisory Board to the Management Board, the election of one new Supervisory Board and one substitute member was also on the agenda.

Dr. Johannes Holzmeister was elected to the Supervisory Board with 100% of the votes. Dr. Johannes Holzmeister is a senior cardiology consultant at UniversitätsSpital Zürich and cofounder and CMO at the Swiss biotech company Cardiorientis AG. He is a graduate in medicine from the Humboldt-University in Berlin.

Dr. Rüdiger Weseloh, currently Senior Director at Merck Serono in Darmstadt, was elected as substitute member for Dr. Holzmeister to ensure that no vacancy arises in the Supervisory Board in the event of his resignation.

Furthermore, the Management Board presented and explained the company’s business strategy for the coming years to shareholders at the Annual General Meeting. As well as stepping up its search for a suitable partner for the international marketing of DermaPro[®], CytoTools AG is also planning additional clinical studies on Derma Pro[®], already very well characterized as an active substance, whose application potential is now to be extended to new indications outside its main dermatological focus.

Moreover, the CytoPharma GmbH subsidiary is to intensify its preparations for clinical trials and the generation of initial human data for already existing, promising active substance candidates in the field of cardiovascular diseases.

This press release contains specific future-oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future- oriented statements made. CytoTools is not obligated to update these future-oriented statements.

PRESS RELEASE



CytoTools

About CytoTools:

CytoTools AG is a biotechnology company focused on translating fundamental biology research on the mechanisms of cell growth and programmed cell death into unique therapies that are designed to treat the cause of the disease rather than the symptoms. The Company has developed a robust and diverse pipeline of disease modifying therapies that comprise proprietary small molecules and biologics. These have the potential to provide new treatment options in dermatology, cardiology and angiology, urology and oncology. CytoTools AG is structured as an investment and holding company and as such holds investments in its subsidiaries DermaTools Biotech GmbH (57%) and CytoPharma GmbH (42%).

Contact:

CytoTools AG
Dr. Mark Andre Freyberg
Klappacher Str. 126
D-64285 Darmstadt
Tel.: +49-6151-95158-12
Fax: +49-6151-95158-13
E-Mail: freyberg@cytotools.de

Press and IR contact:

Instinctif Partners
Dr. Robert Mayer/Dorothea Schneider
Rindermarkt 5
80331 Munich
Tel.: +49-89-3090 5189 13
E-Mail: cytotools@instinctif.com